Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Okayama University research: Prevention of RNA virus replication
  • USA - English


News provided by

Okayama University

Nov 28, 2016, 15:00 ET

Share this article

Share toX

Share this article

Share toX

Analyse virus gene information and create an artificial RNA restriction enzyme. Viruses cannot replicate as their gene information is cleaved, which means virus cannot cause diseases.
Analyse virus gene information and create an artificial RNA restriction enzyme. Viruses cannot replicate as their gene information is cleaved, which means virus cannot cause diseases.

Okayama, Japan (PRWEB UK) 29 November 2016 -- Source: Okayama University (JAPAN), Public Relations and Information Strategy

Developing technologies that can inactivate viruses and prevent them from infecting humans could transform the way in which we tackle various diseases. Several methods aiming at inactivating viruses have been tried, including preventing the binding of viral proteins and using artificial enzymes to ‘cleave’, or split, molecules in viral genomes.

By splitting a chosen molecular strand, such as DNA or RNA, essential bonds are broken and the molecule can no longer function correctly. In the case of viruses, integrating DNA or RNA cleaving ability into anti-viral drugs could prevent viral replication and infection within a host. Following recent success cleaving DNA in the human papillomavirus, Takashi Sera and co-workers at Okayama University have now used the same technique to cleave RNA in influenza cell cultures.

Firstly, the team developed artificial RNA restriction enzymes. These enzymes incorporate an artificial RNA binding protein, whose job is to target the correct virus, and an RNA cleaving enzyme that targets a specific domain in the viral RNA in order to create the split. Enzymes created for previous studies targeted the viral PIN domain but with limited success, and so Sera’s team created new RNA restriction enzymes targeting the staphylococcal nuclease (SNase) domain instead.

The researchers compared the ability of the SNase-based enzymes to cleave influenza RNA with PIN-fusion enzymes. They found that the SNase enzymes recognized and completely cleaved their target RNA in five minutes in cultures in the lab; in fact, the SNase enzymes had higher cleavage rates in one minute than the PIN-fusion enzymes had in two hours.

With improvements to the enzymes for use in animal (and eventually human) cells, the SNase restriction enzyme technique could one day prove to be a very powerful tool in the development of anti-viral drugs.

Background
DNA and RNA viruses
Viruses have either DNA or RNA as their genomes. Examples of DNA viruses include herpes, chickenpox and smallpox – they replicate in nuclei after infiltrating host cells. RNA viruses, on the other hand, inject their RNA into host cell cytoplasm where it is then used to synthesize proteins and form replica viruses. RNA viruses include influenza, HIV and Ebola, to name but a few.

Scientists are keen to find ways of preventing both DNA and RNA viral infection and replication inside the body. Such technology could transform the way in which we tackle various diseases. One feasible way of stopping viral replication is to target the genetic machinery involved in the process – namely by cleaving, or splitting, the DNA or RNA strands so that they can no longer function correctly.

The techniques developed by Takashi Sera and his team at Okayama University involves the creation of artificial restriction enzymes – carefully-designed molecules incorporating proteins and enzymes that can home in on, and cleave, specific RNA or DNA targets. Their previous studies have been successful in cleaving DNA in human papillomavirus, and now they have used the same technique to cleave RNA in influenza cell cultures.

Implications of the current study
Following further work on the RNA restriction enzymes to ensure they are effective and safe for use in animal (and eventually human) cells, the team hope that their technique could lead to future development of anti-viral drug. Their findings represent a significant step forward in realising this goal.

Figure. Analyse virus gene information and create an artificial RNA restriction enzyme. Viruses cannot replicate as their gene information is cleaved (which means virus cannot cause diseases). This technique can be applied to all kinds of RNA viruses both for animals and plants.

Reference
Tomoaki Mori, Kento Nakamura, Keisuke Masaoka, Yusuke Fujita, Ryosuke Morisada, Koichi Mori, Takamasa Tobimatsu, Takashi Sera. Cleavage of influenza RNA by using a human PUF-based artificial RNA-binding protein–staphylococcal nuclease hybrid. Biochemical and Biophysical Research Communications, Volume 479, Issue 4, 28 October 2016, Pages 736-740.
DOI:10.1016/j.bbrc.2016.09.142.
https://www.ncbi.nlm.nih.gov/pubmed/27693585

About Okayama University (You Tube):
https://www.youtube.com/watch?v=iDL1coqPRYI

Okayama University Medical Research Updates (OU-MRU)
Vol.30:Cancer stem cells’ role in tumor growth revealed
http://www.okayama-u.ac.jp/eng/research_highlights/index_id41.html

S. Kinoshita, Okayama University, +81 9065213797, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.